NMPA and NHC Jointly Issued the Announcement on Regulations for the Administration of Drug Clinical Trial Institutions

According to the newly revised Drug Administration Law of the People's Republic of China, drug clinical trial institutions shall be subject to record filing management in lieu of accreditation. NMPA has formulated, in conjunction with the National Health and Health Commission (NHC), the Regulations for the Administration of Drug Clinical Trial Institutions, which has been released on November 29, 2019, and shall take effect as from December 1, 2019.